
Feature|Articles|May 5, 2026
Psychedelic Therapy EO Is a Major Step for Mental Health, but Access Barriers Remain, Experts Say
Author(s)Giuliana Grossi
Fact checked by: Christina Mattina
New executive order fast-tracks psychedelic therapy research for veterans, but VA rollout, DEA rescheduling, and insurance hurdles still loom.
Advertisement
Advertisement
For decades, psychedelic medicine has occupied a complex and often contentious space between restrictive federal scheduling and emerging clinical research. However, a recent
Related to this article

Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.

In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.

Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.

Experts at GOLD 2026 say targeted case finding, AI, and guideline-based treatment can close COPD’s diagnostic gap and improve patient outcomes.

AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.

In 459 patients with FLT3-ITD AML given high-dose anthracycline induction, a high allelic ratio was not linked to survival.

From 9.6 million US diabetic retinopathy cases to a new FDA warning on GLP-1s, here are 5 things to know about diabetic eye disease this November.
Advertisement
Advertisement

